Biosimilari in oncologia. SB3

Dagli studi preclinici agli studi clinici

Translated title of the contribution: Biosimilars in oncology. Focus on SB3 studies

Marzia Del Re, Lucia Del Mastro

Research output: Contribution to journalArticle

Abstract

A phase III study compared SB3, a trastuzumab biosimilar, with trastuzumab originator in 800 HER2 positive breast cancer patients undergoing neoadjuvant chemotherapy. The aim of the study was to demonstrate the equivalence between the two drugs in terms of pathological complete responses. The total pathologic complete response rates were 51.7% and 42.0% with SB3 and trastuzumab, respectively. Equivalence for efficacy was demonstrated between SB3 and trastuzumab. Safety and immunogenicity were comparable.

Original languageItalian
Pages (from-to)531-539
Number of pages9
JournalRecenti Progressi in Medicina
Volume109
Issue number11
Publication statusPublished - Nov 1 2018

Fingerprint

Biosimilar Pharmaceuticals
Breast Neoplasms
Safety
Drug Therapy
Trastuzumab
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Biosimilari in oncologia. SB3 : Dagli studi preclinici agli studi clinici. / Del Re, Marzia; Del Mastro, Lucia.

In: Recenti Progressi in Medicina, Vol. 109, No. 11, 01.11.2018, p. 531-539.

Research output: Contribution to journalArticle

@article{bf78a5e6a5dd454da33d3b9fe1a11fb3,
title = "Biosimilari in oncologia. SB3: Dagli studi preclinici agli studi clinici",
abstract = "A phase III study compared SB3, a trastuzumab biosimilar, with trastuzumab originator in 800 HER2 positive breast cancer patients undergoing neoadjuvant chemotherapy. The aim of the study was to demonstrate the equivalence between the two drugs in terms of pathological complete responses. The total pathologic complete response rates were 51.7{\%} and 42.0{\%} with SB3 and trastuzumab, respectively. Equivalence for efficacy was demonstrated between SB3 and trastuzumab. Safety and immunogenicity were comparable.",
keywords = "Biosimilar, Breast cancer, SB3, Trastuzumab",
author = "{Del Re}, Marzia and {Del Mastro}, Lucia",
year = "2018",
month = "11",
day = "1",
language = "Italian",
volume = "109",
pages = "531--539",
journal = "Recenti Progressi in Medicina",
issn = "0034-1193",
publisher = "Il Pensiero Scientifico Editore s.r.l.",
number = "11",

}

TY - JOUR

T1 - Biosimilari in oncologia. SB3

T2 - Dagli studi preclinici agli studi clinici

AU - Del Re, Marzia

AU - Del Mastro, Lucia

PY - 2018/11/1

Y1 - 2018/11/1

N2 - A phase III study compared SB3, a trastuzumab biosimilar, with trastuzumab originator in 800 HER2 positive breast cancer patients undergoing neoadjuvant chemotherapy. The aim of the study was to demonstrate the equivalence between the two drugs in terms of pathological complete responses. The total pathologic complete response rates were 51.7% and 42.0% with SB3 and trastuzumab, respectively. Equivalence for efficacy was demonstrated between SB3 and trastuzumab. Safety and immunogenicity were comparable.

AB - A phase III study compared SB3, a trastuzumab biosimilar, with trastuzumab originator in 800 HER2 positive breast cancer patients undergoing neoadjuvant chemotherapy. The aim of the study was to demonstrate the equivalence between the two drugs in terms of pathological complete responses. The total pathologic complete response rates were 51.7% and 42.0% with SB3 and trastuzumab, respectively. Equivalence for efficacy was demonstrated between SB3 and trastuzumab. Safety and immunogenicity were comparable.

KW - Biosimilar

KW - Breast cancer

KW - SB3

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=85058555878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058555878&partnerID=8YFLogxK

M3 - Articolo

VL - 109

SP - 531

EP - 539

JO - Recenti Progressi in Medicina

JF - Recenti Progressi in Medicina

SN - 0034-1193

IS - 11

ER -